Schrödinger, Inc.
Moat Score — Schrödinger, Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Decades of accumulated physics-based modeling IP, deep academic adoption at over 1,750 institutions, and embedded workflows (like LiveDesign) at the largest pharmaceutical companies represent genuine, hard-to-replicate intangible assets. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Schrödinger is not a low-cost provider; it remains unprofitable with a $103.3 million net loss in 2025, reflecting heavy ongoing R&D and platform investment rather than any structural cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Deep penetration and 96% gross dollar retention among commercial pharma customers suggest the platform commands real pricing durability once embedded, though declining net dollar retention (100% vs. 113%) signals some softening expansion pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Computational drug discovery software is not a network-effect business; one customer's use of the platform does not directly make it more valuable to another customer, though broad academic adoption does build a talent pipeline familiar with the tools. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once pharmaceutical R&D teams build discovery workflows around Schrödinger's LiveDesign and modeling tools, switching to a different platform requires significant retraining and workflow disruption, reflected in the 96% gross dollar retention rate. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Physics-based computational drug discovery has moderate barriers to entry given the decades of scientific development behind Schrödinger's platform, but numerous AI/ML-driven competitors have emerged, limiting how much efficient scale alone protects its position. |